[go: up one dir, main page]

IS2305B - Pýrrólo[2,3-d]pýrimídín efnasambönd sem ónæmisbælandi miðlar - Google Patents

Pýrrólo[2,3-d]pýrimídín efnasambönd sem ónæmisbælandi miðlar

Info

Publication number
IS2305B
IS2305B IS6606A IS6606A IS2305B IS 2305 B IS2305 B IS 2305B IS 6606 A IS6606 A IS 6606A IS 6606 A IS6606 A IS 6606A IS 2305 B IS2305 B IS 2305B
Authority
IS
Iceland
Prior art keywords
pyrrolo
immunosuppressive agents
pyrimidine compounds
pyrimidine
compounds
Prior art date
Application number
IS6606A
Other languages
English (en)
Other versions
IS6606A (is
Inventor
Andrew Blumenkopf Todd
Edward Flanagan Mark
John Munchhof Michael
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS6606A publication Critical patent/IS6606A/is
Publication of IS2305B publication Critical patent/IS2305B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS6606A 2000-06-26 2002-10-31 Pýrrólo[2,3-d]pýrimídín efnasambönd sem ónæmisbælandi miðlar IS2305B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21428700P 2000-06-26 2000-06-26
PCT/IB2001/000975 WO2002000661A1 (en) 2000-06-26 2001-06-05 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS

Publications (2)

Publication Number Publication Date
IS6606A IS6606A (is) 2002-10-31
IS2305B true IS2305B (is) 2007-10-15

Family

ID=22798508

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6606A IS2305B (is) 2000-06-26 2002-10-31 Pýrrólo[2,3-d]pýrimídín efnasambönd sem ónæmisbælandi miðlar

Country Status (48)

Country Link
US (4) US6696567B2 (is)
EP (2) EP1686130B1 (is)
JP (1) JP4068958B2 (is)
KR (1) KR100516419B1 (is)
CN (1) CN100351253C (is)
AP (1) AP1911A (is)
AR (1) AR029279A1 (is)
AT (2) ATE423120T1 (is)
AU (1) AU784297C (is)
BG (1) BG107236A (is)
BR (1) BR0111561A (is)
CA (1) CA2412560C (is)
CU (1) CU23263B7 (is)
CZ (1) CZ20023993A3 (is)
DE (2) DE60137734D1 (is)
DK (2) DK1294724T3 (is)
DO (1) DOP2001000200A (is)
DZ (1) DZ3359A1 (is)
EA (1) EA006153B1 (is)
EC (1) ECSP014105A (is)
EE (1) EE200200711A (is)
ES (2) ES2318605T3 (is)
GE (1) GEP20053541B (is)
GT (1) GT200100117A (is)
HR (1) HRP20021000A2 (is)
HU (1) HUP0301114A3 (is)
IL (2) IL152771A0 (is)
IS (1) IS2305B (is)
MA (1) MA26917A1 (is)
MX (1) MXPA03000068A (is)
MY (1) MY127236A (is)
NO (1) NO324934B1 (is)
NZ (1) NZ522364A (is)
OA (1) OA12292A (is)
PA (1) PA8521101A1 (is)
PE (1) PE20020381A1 (is)
PL (1) PL359563A1 (is)
PT (1) PT1294724E (is)
PY (1) PY0115298A (is)
SI (1) SI1294724T1 (is)
SK (1) SK17342002A3 (is)
SV (1) SV2002000506A (is)
TN (1) TNSN01095A1 (is)
TW (1) TWI243820B (is)
UA (1) UA74370C2 (is)
WO (1) WO2002000661A1 (is)
YU (1) YU83302A (is)
ZA (1) ZA200210275B (is)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20004727A3 (cs) * 1998-06-19 2002-03-13 Pfizer Products Inc. Deriváty pyrrolo[2,3-d] pyrimidinu
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
AU3208200A (en) 1999-01-13 2000-08-01 Research Foundation Of The State University Of New York, The A novel method for designing protein kinase inhibitors
MXPA02005675A (es) 1999-12-10 2002-09-02 Pfizer Prod Inc Compuestos de pirrolo(2,3-d)pirimidina.
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
WO2003035621A1 (en) * 2001-10-22 2003-05-01 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
RS51752B (sr) 2002-07-29 2011-12-31 Rigel Pharmaceuticals Metode tretiranja i prevencije autoimunih oboljenja jedinjenjima 2,4-pirimidindiamina
EP1388541A1 (en) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
NZ539901A (en) * 2002-11-26 2007-09-28 Pfizer Prod Inc Method of treatment of transplant rejection
SE0300456D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
SE0300458D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
SE0300457D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
EP1647546B1 (en) * 2003-07-15 2012-05-02 Dainippon Sumitomo Pharma Co., Ltd. Novel heteroaryl derivative
NZ545270A (en) 2003-07-30 2010-04-30 Rigel Pharmaceuticals Inc 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
BRPI0416909A (pt) * 2003-11-25 2007-01-16 Pfizer Prod Inc método de tratamento de aterosclerose
WO2005097129A2 (en) * 2004-04-05 2005-10-20 Takeda Pharmaceutical Company Limited 6-azaindole compound
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
EP1768982A2 (en) * 2004-06-29 2007-04-04 Amgen Inc. Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity
EP1781287A4 (en) * 2004-08-13 2008-02-27 Genentech Inc THIAZOL-BASED INHIBITORS OF ATP-USING ENZYMES
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US7662824B2 (en) 2005-03-18 2010-02-16 Janssen Pharmaceutica Nv Acylhydrazones as kinase modulators
KR20080025039A (ko) 2005-05-13 2008-03-19 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
WO2007046867A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
SG137989A1 (en) 2005-06-08 2008-01-28 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
KR20080026654A (ko) 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
PL1966202T3 (pl) * 2005-12-13 2012-02-29 Incyte Holdings Corp Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
WO2008029237A2 (en) * 2006-09-05 2008-03-13 Pfizer Products Inc. Combination therapies for rheumatoid arthritis
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079965A1 (en) 2006-12-22 2008-07-03 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
KR20090106604A (ko) 2007-01-12 2009-10-09 아스텔라스세이야쿠 가부시키가이샤 축합 피리딘 화합물
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
CN103524509B (zh) 2007-06-13 2016-03-02 因塞特控股公司 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐
NZ585261A (en) 2007-10-11 2011-10-28 Astrazeneca Ab Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors
NZ587589A (en) 2008-02-15 2012-10-26 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
BRPI0909040B8 (pt) 2008-03-11 2021-05-25 Incyte Holdings Corp derivados de azetidina e ciclobutano, seus usos, e composição
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
ES2546502T3 (es) 2008-04-16 2015-09-24 Portola Pharmaceuticals, Inc. 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
EP2324020A2 (en) * 2008-08-01 2011-05-25 Biocryst Pharmaceuticals, Inc. Piperidine derivatives as jak3 inhibitors
PL2384326T3 (pl) 2008-08-20 2014-09-30 Zoetis Services Llc Związki pirolo[2,3-d]pirymidyonowe
US8385364B2 (en) * 2008-09-24 2013-02-26 Nec Laboratories America, Inc. Distributed message-passing based resource allocation in wireless systems
JP2012517448A (ja) * 2009-02-11 2012-08-02 リアクション バイオロジー コープ． 選択的キナーゼ阻害剤
DK2414356T3 (en) 2009-04-03 2015-12-14 Hoffmann La Roche PROPAN-1-sulfonic acid {3- [5- (4-CHLORO-PHENYL) -1H-pyrrolo [2,3-b] pyridine-3- carbonyl] -2,4-difluorophenyl) -AMIDSAMMENSÆTNINGER AND USES THEREOF
CN104817561B (zh) 2009-04-20 2017-06-13 奥斯拜客斯制药有限公司 Janus激酶3的哌啶抑制剂
AR076920A1 (es) 2009-05-22 2011-07-20 Incyte Corp 3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)octano-o heptano--nitrilo como inhibidores de jak
MX2011012353A (es) 2009-05-22 2011-12-14 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
CN102711473B (zh) 2009-09-04 2016-11-09 比奥根Ma公司 布鲁顿酪氨酸激酶抑制剂
EA021478B1 (ru) 2009-10-09 2015-06-30 Инсайт Корпорейшн ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
WO2011045702A1 (en) 2009-10-15 2011-04-21 Pfizer Inc. Pyrrolo[2,3-d] pyrimidine compounds
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
WO2011075334A1 (en) 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
EP2531508A1 (en) * 2010-02-05 2012-12-12 Pfizer Inc. Pyrrolo [ 2, 3 - d]pyrimidine urea compounds as jak inhibitors
WO2011104652A2 (en) * 2010-02-24 2011-09-01 Pfizer Inc. Veterinary compositions
LT3354652T (lt) 2010-03-10 2020-09-25 Incyte Holdings Corporation Piperidin-4-il azetidino dariniai kaip jak1 inhibitoriai
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
TWI499421B (zh) 2010-05-21 2015-09-11 Incyte Corp Ｊａｋ抑制劑的局部製劑
JP5749341B2 (ja) 2010-08-20 2015-07-15 ハチソン メディファーマ リミテッド ピロロピリミジン化合物およびその使用
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
WO2012061428A2 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
MX344478B (es) 2010-11-19 2016-12-16 Incyte Holdings Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de janus cinasas (jak).
HUE040136T2 (hu) 2011-02-07 2019-02-28 Plexxikon Inc Vegyületek és eljárások kináz modulációra és azok indikációi
US9993480B2 (en) 2011-02-18 2018-06-12 Novartis Pharma Ag mTOR/JAK inhibitor combination therapy
US9115133B2 (en) 2011-03-22 2015-08-25 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
RS59568B1 (sr) 2011-04-01 2019-12-31 Astrazeneca Ab Terapeutski tretman
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
EA026939B1 (ru) 2011-11-23 2017-06-30 Портола Фармасьютикалз, Инк. Пиразиновые ингибиторы киназы
CA2856722C (en) 2011-11-30 2022-11-22 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
US20140329786A1 (en) 2011-11-30 2014-11-06 Astrazeneca Ab Combination treatment of cancer
CA2857977C (en) * 2011-12-21 2020-10-20 Jiangsu Hengrui Medicine Co., Ltd. Pyrrole six-membered heteroaryl ring derivative, preparation method thereof, and medicinal uses thereof
EP3216792B1 (en) 2012-03-29 2020-05-27 G1 Therapeutics, Inc. Lactam kinase inhibitors
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
EP2897962A1 (en) 2012-09-21 2015-07-29 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
IL297429A (en) 2012-11-15 2022-12-01 Incyte Holdings Corp Sustained release dosage forms of roxolitinib
US9481679B2 (en) 2012-12-17 2016-11-01 Sun Pharmaceutical Industries Limited Process for the preparation of tofacitinib and intermediates thereof
EA027879B1 (ru) 2013-02-22 2017-09-29 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
HRP20211922T1 (hr) 2013-03-06 2022-03-04 Incyte Holdings Corporation Postupci i intermedijeri za pripravu jak inhibitora
CN105407723A (zh) 2013-03-15 2016-03-16 G1治疗公司 高效的抗赘生剂和抗增生剂
EP3653209A1 (en) 2013-03-15 2020-05-20 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
WO2014194741A1 (zh) * 2013-06-07 2014-12-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐及其制备方法
PE20160223A1 (es) 2013-08-07 2016-04-27 Incyte Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1
RU2672725C2 (ru) * 2013-08-22 2018-11-19 Дженентек, Инк. Способ получения соединения
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds
UA117040C2 (uk) * 2013-12-05 2018-06-11 Пфайзер Інк. ПІРОЛО[2,3-d]ПІРИМІДИНІЛ-, ПІРОЛО[2,3-b]ПІРАЗИНІЛ- ТА ПІРОЛО[2,3-d]ПІРИДИНІЛАКРИЛАМІДИ
US20150297606A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
CN106536518B (zh) * 2014-05-19 2020-05-12 勃林格殷格翰动物保健美国公司 驱蠕虫化合物
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
EP3180344B1 (en) 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
KR101710127B1 (ko) * 2014-08-29 2017-02-27 한화제약주식회사 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
CN105566327A (zh) 2014-10-09 2016-05-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法
SI3216790T1 (sl) * 2014-11-05 2020-02-28 Jiangsu Hengrui Medicine Co., Ltd., Kristalinična oblika bisulfata inhibitorja JAK-kinaze in postopek priprave le-te
CN108349977B (zh) * 2015-01-20 2021-05-25 无锡福祈制药有限公司 Jak抑制剂
WO2016178110A1 (en) 2015-05-01 2016-11-10 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
KR101771219B1 (ko) 2015-08-21 2017-09-05 양지화학 주식회사 야누스 키나제 1 선택적 억제제 및 그 의약 용도
CN108472298B (zh) 2015-11-24 2021-04-20 深圳阿拉丁医疗科技有限公司 选择性激酶抑制剂
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
JP7214632B2 (ja) 2016-07-21 2023-01-30 バイオジェン エムエー インク． ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
CN106120090A (zh) * 2016-08-31 2016-11-16 飞佛特种纺织品（宁波）有限公司 一种防刮擦阳光面料的制备方法
CA3040981A1 (en) 2016-11-23 2018-05-31 Bing Liu Preparation method for and intermediate of pyrrolo six-membered heteroaromatic ring derivative
NZ754865A (en) 2017-01-06 2023-07-28 G1 Therapeutics Inc Combination therapy for the treatment of cancer
CN106831538B (zh) * 2017-01-22 2019-06-25 苏州楚凯药业有限公司 托法替尼中间体的制备方法
JP2020509004A (ja) * 2017-02-27 2020-03-26 ヤンセン ファーマシューティカ エヌ．ベー． Ｏｇａ阻害剤としての、ピペリジン、モルホリンまたはピペラジンで置換されている［１，２，４］−トリアゾロ［１，５−ａ］−ピリミジニル誘導体
CN107337676A (zh) * 2017-06-08 2017-11-10 江苏正大清江制药有限公司 一种托法替布起始原料的制备方法
EA201992768A1 (ru) 2017-06-29 2020-05-19 Г1 Терапьютикс, Инк. Морфологические формы g1t38 и способы их получения
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EP3746429B1 (en) 2018-01-30 2022-03-09 Incyte Corporation Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
BR112020019814A2 (pt) 2018-03-30 2021-01-05 Incyte Corporation Tratamento de hidradenite supurativa usando inibidores jak
WO2020041770A1 (en) 2018-08-24 2020-02-27 G1 Therapeutics, Inc. Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
EP3946606B1 (en) 2019-03-27 2025-01-01 Insilico Medicine IP Limited Bicyclic jak inhibitors and uses thereof
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
PH12022551052A1 (en) 2019-11-22 2023-05-29 Incyte Corp Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
AU2021287998A1 (en) 2020-06-11 2023-02-02 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022117075A1 (zh) * 2020-12-04 2022-06-09 广州费米子科技有限责任公司 氮杂并环化合物、其制备方法及其用途

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3670079A (en) * 1970-10-06 1972-06-13 Merck & Co Inc Anabolic agents
US4997936A (en) * 1977-10-19 1991-03-05 Merck & Co., Inc. 2-carbamimidoyl-6-substituted-1-carbadethiapen-2-em-3-carboxylic acids
US4456464A (en) * 1982-05-19 1984-06-26 Zoecon Corporation Phenoxy- and pyridyloxy-phenoxyalkyl phosphinates and related sulfur compounds for weed control
US4526608A (en) * 1982-07-14 1985-07-02 Zoecon Corporation Certain 2-pyridyloxyphenyl-oximino-ether-carboxylates, herbicidal compositions containing same and their herbicidal method of use
US4590282A (en) * 1984-09-24 1986-05-20 Sandoz Ltd. Pest control agents
US4933339A (en) * 1985-08-21 1990-06-12 Rohm And Haas Company (2-cyano-2-arylethyl)pyridine compounds useful in controlling fungicidal activity
CA1328333C (en) * 1988-03-04 1994-04-05 Quirico Branca Amino acid derivatives
US4879309A (en) * 1988-09-27 1989-11-07 Schering Corporation Mercapto-acylamino acids as antihypertensives
US5356903A (en) * 1993-04-22 1994-10-18 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolines
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DK0682027T3 (da) 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidinderivater med antiproliferativ virkning
WO1996040142A1 (en) 1995-06-07 1996-12-19 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
AU6478396A (en) 1995-07-05 1997-02-05 E.I. Du Pont De Nemours And Company Fungicidal pyrimidinones
IL122855A (en) 1995-07-06 2004-08-31 Novartis Ag History of N-Phenyl (Alkyl) - 7H-Pyrolo [-3,2d] Pyrimidine - 4 Amine, their preparation and pharmaceutical preparations containing them
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
PL321296A1 (en) 1995-11-14 1997-12-08 Pharmacia & Upjohn Spa Derivatives of aryl and heteroaryl purine
ATE217873T1 (de) 1996-01-23 2002-06-15 Novartis Erfind Verwalt Gmbh Pyrrolopyrimidinen und verfahren zu deren herstellung
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU1794697A (en) 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
PE91098A1 (es) 1996-07-13 1999-01-15 Glaxo Group Ltd DERIVADOS DE PIRIDO[3,4-d]PIRIMIDINA
ATE384062T1 (de) 1996-08-23 2008-02-15 Novartis Pharma Gmbh Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
AU4718997A (en) 1996-11-27 1998-06-22 Pfizer Inc. Fused bicyclic pyrimidine derivatives
KR20000070751A (ko) 1997-02-05 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
US6187552B1 (en) 1997-03-24 2001-02-13 Pharmacia & Upjohn Company Method for identifying inhibitors of JAK2/cytokine receptor binding
AU3378799A (en) 1998-04-02 1999-10-25 Neurogen Corporation Aminoalkyl substituted pyrrolo(2,3-b)pyridine and pyrrolo(2,3-d)pyrimidine derivatives: modulators of crf1 receptors
CA2333392A1 (en) 1998-05-28 1999-12-02 Parker Hughes Institute Quinazolines for treating brain tumor
CZ20004727A3 (cs) * 1998-06-19 2002-03-13 Pfizer Products Inc. Deriváty pyrrolo[2,3-d] pyrimidinu
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
AU4851599A (en) 1998-06-30 2000-01-17 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
ATE292121T1 (de) 1998-08-21 2005-04-15 Parker Hughes Inst Chinazolinderivate
BR9913887A (pt) * 1998-09-18 2001-10-23 Basf Ag Composto, e, métodos de inibir a atividade de proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
EP1224187B1 (en) * 1999-09-30 2006-02-22 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
MXPA02005675A (es) * 1999-12-10 2002-09-02 Pfizer Prod Inc Compuestos de pirrolo(2,3-d)pirimidina.
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US7253166B2 (en) * 2003-04-22 2007-08-07 Irm Llc 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells
AR050365A1 (es) * 2004-08-02 2006-10-18 Osi Pharm Inc Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos.

Also Published As

Publication number Publication date
PT1294724E (pt) 2006-07-31
UA74370C2 (uk) 2005-12-15
ES2257410T3 (es) 2006-08-01
HRP20021000A2 (en) 2005-02-28
AU784297B2 (en) 2006-03-02
SI1294724T1 (sl) 2006-08-31
CN100351253C (zh) 2007-11-28
CN1439010A (zh) 2003-08-27
PE20020381A1 (es) 2002-05-13
IL152771A (en) 2009-06-15
ATE423120T1 (de) 2009-03-15
DK1686130T3 (da) 2009-04-06
SK17342002A3 (sk) 2004-06-08
CA2412560C (en) 2008-12-30
PY0115298A (es) 2003-11-03
KR20030017561A (ko) 2003-03-03
EE200200711A (et) 2004-06-15
NO20026030D0 (no) 2002-12-16
US6696567B2 (en) 2004-02-24
NO20026030L (no) 2002-12-16
CU23263B7 (es) 2008-03-14
MA26917A1 (fr) 2004-12-20
EP1294724B1 (en) 2006-04-19
OA12292A (en) 2003-11-11
PA8521101A1 (es) 2002-04-25
US7192963B2 (en) 2007-03-20
US20030220353A1 (en) 2003-11-27
JP2004501922A (ja) 2004-01-22
HK1054930A1 (en) 2003-12-19
ZA200210275B (en) 2003-12-19
TNSN01095A1 (fr) 2005-11-10
EA200201096A1 (ru) 2003-04-24
DOP2001000200A (es) 2003-02-15
CZ20023993A3 (cs) 2004-02-18
AP1911A (en) 2008-10-30
ATE323704T1 (de) 2006-05-15
AR029279A1 (es) 2003-06-18
GEP20053541B (en) 2005-06-10
NO324934B1 (no) 2008-01-07
US20020068746A1 (en) 2002-06-06
MY127236A (en) 2006-11-30
HUP0301114A2 (hu) 2003-08-28
EA006153B1 (ru) 2005-10-27
DK1294724T3 (da) 2006-07-17
AP2002002695A0 (en) 2002-12-31
DE60118917T2 (de) 2006-11-30
EP1294724A1 (en) 2003-03-26
AU6053801A (en) 2002-01-08
KR100516419B1 (ko) 2005-09-23
TWI243820B (en) 2005-11-21
EP1686130A1 (en) 2006-08-02
MXPA03000068A (es) 2003-09-25
AU784297C (en) 2007-01-11
PL359563A1 (pl) 2004-08-23
ES2318605T3 (es) 2009-05-01
DE60118917D1 (de) 2006-05-24
CA2412560A1 (en) 2002-01-03
US20070161666A1 (en) 2007-07-12
ECSP014105A (es) 2002-01-25
DE60137734D1 (de) 2009-04-02
HUP0301114A3 (en) 2004-11-29
BR0111561A (pt) 2003-09-09
YU83302A (sh) 2005-09-19
US20050197349A1 (en) 2005-09-08
WO2002000661A1 (en) 2002-01-03
IL152771A0 (en) 2003-06-24
US6962993B2 (en) 2005-11-08
NZ522364A (en) 2004-09-24
GT200100117A (es) 2002-01-31
DZ3359A1 (fr) 2002-01-03
BG107236A (bg) 2003-09-30
JP4068958B2 (ja) 2008-03-26
IS6606A (is) 2002-10-31
SV2002000506A (es) 2002-10-24
EP1686130B1 (en) 2009-02-18

Similar Documents

Publication Publication Date Title
IS2305B (is) Pýrrólo[2,3-d]pýrimídín efnasambönd sem ónæmisbælandi miðlar
GEP20074227B (en) PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS
DK1235830T3 (da) Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer
AU2002357773A1 (en) 1,6 naphthyridines useful as inhibitors of syk kinase
WO2004031401A3 (en) Novel tyrosine kinases inhibitors
WO2002020489A3 (en) QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE
WO2002096905A8 (en) Thiazole compounds useful as inhibitors of protein kinases
MXPA02005844A (es) Inhibidores de cinasas de proteina.
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
WO2005028443A3 (en) Protein tyrosine kinase enzyme inhibitors
WO2002085906A3 (en) Phthalazinones derivatives useful as pde4/7 inhibitors
WO2003051879A8 (en) Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
DE602004012559D1 (de) 4-SUBSTITUIERTE DERIVATE VON PYRAZOLOi3,4-D PYRIMIDIN UND DEREN VERWENDUNGEN
WO2002024663A3 (en) Pyrimidine compounds and their use
MXPA03003923A (es) Compuestos de n-([1,2,4]triazoloazinil)tiofensulfonamida como herbicidas.
CA2452036A1 (en) 6-'2-(phosphonomethoxy) alkoxy pyrimidine derivatives having antiviral activity
CA2423357A1 (en) Fused heterocyclic derivatives as phosphodiesterase inhibitors
UY26791A1 (es) Compuestos de pirrol (2,3-d) pirimidina
CR6832A (es) COMPUESTOS DE PIRROLO (2,3-d) PIRIMIDINA